Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

enrolling_by_invitation133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationnot_applicable

Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults

NCT06777173
completedphase_2

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

NCT02634294
completedphase_1

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

NCT03554005

Clinical Trials (3)

Showing 3 of 3 trials
NCT06777173Not Applicable

Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults

Enrolling By Invitation
NCT02634294Phase 2

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Completed
NCT03554005Phase 1

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3